Skip to main
BIIB
BIIB logo

Biogen (BIIB) Stock Forecast & Price Target

Biogen (BIIB) Analyst Ratings

Based on 42 analyst ratings
Buy
Strong Buy 36%
Buy 33%
Hold 31%
Sell 0%
Strong Sell 0%

Bulls say

Biogen's positive outlook is supported by strong sales growth in its multiple sclerosis drug portfolio, particularly due to seasonal channel dynamics affecting Vumerity, and the anticipated expansion into international markets such as China, where significant sales potential exists. The company is successfully ramping up key new product launches, including Leqembi, Skyclarys, and Zurzuvae, which are exceeding consensus expectations, thereby enhancing revenue generation prospects. Furthermore, Biogen's strategic focus on business development initiatives and a robust biosimilar pipeline suggest a path towards achieving substantial cost savings and sustainable growth through new therapeutic offerings and partnerships.

Bears say

Biogen is anticipating a mid-single digit decline in total revenue for 2025, primarily due to the impending entry of a biosimilar for Tysabri in the U.S. and increasing generic competition for Tecfidera, which is expected to significantly impact the multiple sclerosis (MS) segment. Despite efforts to offset these declines with revenue growth from new product launches, management's guidance indicates that core pharmaceutical revenue will also decrease, largely attributable to the MS revenue erosion. The company has expressed concerns over inventory challenges and the slower volume growth trajectory for recently approved products, reinforcing a bearish outlook on its financial performance moving forward.

Biogen (BIIB) has been analyzed by 42 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 33% recommend Buy, 31% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Biogen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Biogen (BIIB) Forecast

Analysts have given Biogen (BIIB) a Buy based on their latest research and market trends.

According to 42 analysts, Biogen (BIIB) has a Buy consensus rating as of Jul 10, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $252.36, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $252.36, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Biogen (BIIB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.